

Special Issue

Nanocarriers in Cardiovascular Medicine: Current Applications and Future Perspectives

Message from the Guest Editors

There are various options available for treating CVDs, including synthetic drugs and herbal medicines. Nanocarriers can improve medication maintenance in the circulatory system, increase drug–target interaction, and reduce undesirable effects. Although nanocarriers offer therapeutic advantages, systematic efforts are still needed in order to establish the effectiveness and safety of these formulations. For this Special Issue, we invite researchers to submit studies on nanocarrier design, targeted drug delivery, pharmacokinetics, and pharmacodynamics, focusing on advancements in the treatment of cardiovascular diseases. We will accept both original research and review articles. Potential submission topics include, but are not restricted to, the following:

- Nanoparticle-delivered dosage forms;
- Characterization of nanocarrier formulations;
- Quality control in nanocarrier development;
- Excipient–drug interactions;
- Pharmacokinetic studies in nanocarrier discovery;
- Pre-clinical and clinical studies on nanocarrier formulations;
- Review studies on the use of nanocarriers in cardiovascular diseases.

Guest Editors

Dr. Arquimedes Gasparotto Junior

Laboratory of Cardiovascular Pharmacology (LaFaC), Federal University of Grande Dourados (UFGD), Rodovia Dourados-Itahum, km 12, P.O. Box 533, Dourados 79804-970, MS, Brazil

Dr. Francislaine Aparecida Dos Reis Lívero

Laboratory of Cardiometabolic Pharmacology, Department of Pharmacology, Federal University of Parana, Curitiba 81530-900, PR, Brazil

Deadline for manuscript submissions

31 August 2025



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/232385

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).